RT Journal Article
SR Electronic
T1 Gout, rheumatoid arthritis and the risk of death from COVID-19: an analysis of the UK Biobank
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.06.20227405
DO 10.1101/2020.11.06.20227405
A1 Topless, Ruth K
A1 Phipps-Green, Amanda
A1 Leask, Megan
A1 Dalbeth, Nicola
A1 Stamp, Lisa K
A1 Robinson, Philip C
A1 Merriman, Tony R
YR 2021
UL http://medrxiv.org/content/early/2021/02/20/2020.11.06.20227405.abstract
AB Objectives To assess whether gout and / or rheumatoid arthritis (RA) are risk factors for coronavirus disease 19 (COVID-19) diagnosis. To assess whether gout and / or RA are risk factors for death with COVID-19.Methods We used data from the UK Biobank. Multivariable-adjusted logistic regression was employed in the following analyses: Analysis A, to test for association between gout or RA and COVID-19 diagnosis (n=473,139); Analysis B, to test for association between gout or RA and death with COVID-19 in a case-control cohort of people who died or survived with COVID-19 (n=2,059); Analysis C, to test for association with gout or RA and death with COVID-19 in the entire UK Biobank cohort (n=473,139)Results RA, but not gout, associated with COVID-19 diagnosis in analysis A. Neither RA nor gout associated with risk of death in the COVID-19-diagnosed group in analysis B. However RA associated with risk of death related to COVID-19 using the UK Biobank cohort in analysis C independent of comorbidities and other measured risk factors (OR=1.9 [95% CI 1.2 ; 3.0]). Gout was not associated with death related to COVID-19 in the same UK Biobank analysis (OR=1.2 [95% CI 0.8 ; 1.7]).Conclusion Rheumatoid arthritis is a risk factor for death with COVID-19 using the UK Biobank cohort. These findings require replication in larger data sets that also allow inclusion of a wider range of factors.Key messages Information on the risk of death from COVID-19 for people with gout and rheumatoid arthritis is scarce.In an analysis of the UK Biobank there is an increased risk of death related to COVID-19 for people with rheumatoid arthritis independent of included co-morbidities, but not gout.The findings need to be replicated in other datasets where the influence of therapies for rheumatoid arthritis can be tested.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by the Health Research Council of New Zealand.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:North West Multi-centre Research Ethics Committee (MREC) (United Kingdom)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll individual level data from which the results are derived are publicly-available from the UK Biobank.